Welcome to BioSeeker Group!

Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3724
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides.

    To find out more about Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
Abbott
AC Immune
Acceleron Pharma
Access
Active Biotech
Adaptimmune
Adherex
Advantagene
Advaxis
Advenchen
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anchor Therapeutics
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Anza Therapeutics
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Arana Therapeutics
Ardana
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
Biokine Therapeutics
BioNTech
BioSante
Biostar
BioVex
Boehringer Ingelheim
Bolder BioTechnology
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
Chiasma
China Sky One Medical
Choongwae
Circadian Technologies
Cleveland BioLabs
Clinuvel
Compugen
Cosmo Pharmaceuticals
CreaGene
CSL
Cue Biotech
Curaxis
CureVac
Curis
Cyclacel
Cytochroma
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Digna Biotech
Dongkook Pharm
Dyax
Eisai
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Epeius Biotechnologies
Esperance Pharmaceuticals
Etubics
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
Formula Pharmaceuticals
Galena Biopharma
GammaCan
Generex
Genmab
GenOdyssee Pharmaceuticals
GENova Biotherapeutics
Genovax
Genticel
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GlycoGenesys
GP Pharm
Gradalis
Green Cross
Gryphon Therapeutics
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
ImClone Systems
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunotope
Immunovaccine
ImmuPharma
Innovive
Inovio
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Karus Therapeutics
Karyon-CTT
Kirax
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Meda
MediGene
Mediolanum
Menarini
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Morvus Technology
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Neurobiological Technologies
NewSouth Innovations
Nidus Laboratories
NIH
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novelix
Noxxon
NPS Pharmaceuticals
Oasmia
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Progen
Progenics Pharmaceuticals
Protagonist
Protein Sciences
Protgen
Protherics
PTC Therapeutics
Q Chip
QLT
Radient Pharmaceuticals
Raptor Pharmaceutical
Receptor BioLogix
Regeneron
responsif
Rexahn
Rigel
Sanofi
Santaris Pharma
Sarepta Therapeutics
Scancell
SciClone Pharmaceuticals
Semafore Pharmaceuticals
Serometrix
Shionogi
Shire
Simcere Pharmaceuticals
Soligenix
Spear Therapeutics
Spectrum Pharmaceuticals
SRI International
Stainwei Biotech
SuperGen
Switch Pharma
SynDevRx
Tactic Pharma
Taiho
TapImmune
Tau Therapeutics
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
UCB
Unigene
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Vical
Wilex
Viragen
Virionics
ViroMed
Xerion
Xigen
Zelos Therapeutics
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abagovomab
abarelix
ABT-510
ADXS11-001
AE-37
AEZS-108
afamelanotide
aflibercept
AGS-003
AMG-386
angiopep+paclitaxel
Angiozyme
ANZ-207
apatinib
ARQ-197
astuprotimut-r
atrasentan
Auto TAG vaccine
AVX-701
axitinib
belagenpumatucel-L
bevacizumab
BIBF-1120
BMS-690514
BP-GMAX-CD1
brivanib alaninate
BV-NSCLC-001
CB-10-01
CBP-501
CDX-1307
cediranib
CG-201
cilengitide
corticorelin acetate
CreaVax-PC
CV-9103
CV-9201
CVac
DCVax-prostate
deslorelin
DI-17E6
dovitinib lactate
E-75
E-7820
emepepimut-S
endostatin
ENMD-2076
enzastaurin hydrochloride
EP-100
everolimus
Exherin
foretinib
fosbretabulin tromethamine
FPI-01
GI-4000
GliaAtak
goserelin
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
GX-301
HBP-347
Her-2/Neu peptides
Hi-8 MEL
histrelin
HS-110
icrucumab
ICT-107
imMucin
IMO-2055
interleukin-12
intetumumab
IPP-204106
ISA-P53-01
JI-101
JX-594
kahalalide F
lanreotide
lenvatinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
LY-2275796
MDX-1379
MGCD-265
MGN-1601
midostaurin
motesanib diphosphate
muparfostat (IV)
MVA-BN Her-2 vaccine
NAFB001
netupitant
NGR-TNF
octreotide
octreotide, LAR
ON-01910
OncoVAX
Onyvax-105
OTS-102
ozarelix
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
PF-4856884
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
ProstAtak
PROSTVAC
PSMA ADC
PTC-299
RAF-265
ramucirumab
regorafenib
Reximmune-C
ridaforolimus
rindopepimut
rintatolimod
romurtide
S-488410
SCIB-1
sipuleucel-T
sirolimus
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
TG-4010
thymalfasin
tipapkinogene sovacivec
tipifarnib
tivozanib
TM-30339
TRC-105
TroVax
vandetanib
vapreotide, immediate-release
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volociximab
VX-001
XL-184
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides.
    To find out more about Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


The MAPK Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 343 companies plus partners who are today developing 463 The MAPK signaling pathway targeting drugs in 1699 developmental projects in cancer across 206 different targets. In addition, there are 2 suspended drugs and another 198 drugs where development has been ceased. Learn More


Triple Analysis: Lung Cancer, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More